Non-Hodgkin lymphoma Posts Page 2 on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Comparison between rituximab and CT-P10 biosimilar medication for the treatment of patients with advanced stage follicular lymphoma

Posted by on Oct 7, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared rituximab (Rituxan) and CT-P10 treatments for patients with previously untreated advanced stage follicular lymphoma. The study concluded that CT-P10 is just as safe and effective as name-brand rituximab.  Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma. It is commonly treated...

Read More

Using erythropoietin mouthwash to reduce the occurrence of oral mucositis in patients receiving autologous stem cell transplantation

Posted by on Oct 7, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at how effective erythropoietin mouthwash was at preventing oral mucositis in cancer patients being treated with autologous stem cell transplantation. The study concluded that rinsing with erythropoietin mouthwash can prevent oral mucositis.  Some background Oral mucositis (OM) is a complication associated with...

Read More

Different types of treatment for patients with early stage mantle cell lymphoma

Posted by on Oct 4, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the outcomes of different types of initial treatment for patients diagnosed with early stage mantle cell lymphoma. The study concluded that a reduced intensity treatment approach is worthwhile for patients with early stage mantle cell lymphoma. Some background Mantle cell lymphoma (MCL) is a type of non-Hodgkin...

Read More

Subcutaneous vs intravenous rituximab treatment for patients with diffuse large B-cell lymphoma

Posted by on Oct 3, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness of rituximab (Rituxen) treatment when given subcutaneously or intravenously for patients with diffuse large B-cell lymphoma. The study concluded that subcutaneous rituximab is just as effective as intravenous rituximab, and has higher patient satisfaction. Some background Diffuse large B-cell...

Read More

Comparison of rituximab and GP2013, a biosimilar medication, in the treatment of patients with follicular lymphoma

Posted by on Oct 2, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared rituximab and GP2013 treatments in patients with previously untreated advanced stage follicular lymphoma. The study concluded that patients treated with GP2013 had similar outcomes to patients treated with rituximab.  Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma. It is commonly...

Read More

Lenalidomide combined with rituximab is an effective first treatment option for follicular lymphoma

Posted by on Sep 26, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effectiveness of lenalidomide (Revlimid) plus rituximab (Rituxan) in previously untreated follicular lymphoma. The authors concluded that this was a safe and effective first-line treatment option. Some background The first treatment often used in follicular lymphoma is rituximab combined with chemotherapy....

Read More

High intensity chemotherapy versus chemotherapy plus autologous stem cell transplantation for young patients with high risk diffuse large B-cell lymphoma

Posted by on Sep 26, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared two different treatment approaches for patients with high-risk diffuse large B-cell lymphoma. The authors concluded that increasing treatment intensity early significantly improves survival for patients with high risk diffuse large B-cell lymphoma.  Some background Diffuse large B-cell lymphoma (DLBCL) is the...

Read More

How anxiety, depression, and unmet patient needs impact the quality of life of patients with diffuse large B-cell lymphoma

Posted by on Sep 26, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at how anxiety and depression influence the quality of life of patients with diffuse large-B cell lymphoma. The study concluded that anxiety, depression, and unmet patient needs negatively impact the physical and emotional wellbeing of patients. Some background Diffuse large B-cell lymphoma (DLBCL) is a common type...

Read More

The use of a blood test to predict future outcomes for patients with relapsed diffuse large B-cell lymphoma

Posted by on Sep 26, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at how effective a blood test was at predicting future outcomes in patients with relapsed or difficult to treat diffuse large B-cell lymphoma. The study concluded that the lymphocyte-to-monocyte ratio blood test is very effective at predicting future outcomes for patients with relapsed or difficult to treat diffuse large...

Read More

The safety and outcomes of lenalidomide treatment for patients with relapsed or difficult to treat mantle cell lymphoma

Posted by on Sep 23, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the use of lenalidomide (Revlimid) treatment for patients with relapsed mantle cell lymphoma. The authors concluded that lenalidomide is generally safe and effective for treating patients with advanced stage relapsed or difficult to treat mantle cell lymphoma. Some background Mantle cell lymphoma (MCL) is an...

Read More

Review of obinutuzumab for follicular lymphoma patients who failed rituximab treatments

Posted by on Sep 23, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This article reviewed the use of obinutuzumab for patients with follicular lymphoma who have failed rituximab treatment. The article concluded that obinutuzumab treatment is useful for follicular lymphoma patients who have not responded well to rituximab regimens.  Some background Follicular lymphoma (FL) is a common type...

Read More